As per NCEP- ATP III, which of the following is not a criterion for metabolic syndrome?

Explanation

## Correct Answer: D. High LDL The NCEP-ATP III criteria for metabolic syndrome require **three or more** of five specific components: (1) abdominal/central obesity (waist circumference >102 cm in men, >88 cm in women by ATP III; Indian cutoffs are lower at >90 cm men, >80 cm women per IDF), (2) elevated triglycerides (≥150 mg/dL), (3) reduced HDL cholesterol (<40 mg/dL in men, <50 mg/dL in women), (4) elevated blood pressure (≥130/85 mmHg), and (5) elevated fasting glucose (≥110 mg/dL, later revised to ≥100 mg/dL). High LDL cholesterol is **not** a diagnostic criterion for metabolic syndrome. While LDL elevation often coexists with metabolic syndrome due to shared pathophysiology (insulin resistance, dyslipidemia), it is not part of the formal diagnostic definition. The syndrome focuses on HDL reduction and triglyceride elevation—the atherogenic dyslipidemia pattern—rather than LDL levels. This distinction is critical in Indian clinical practice where metabolic syndrome prevalence is rising (15–30% in urban populations), and clinicians must differentiate syndrome diagnosis from overall cardiovascular risk stratification, which would include LDL assessment. ## Why the other options are wrong **A. Hypertension** — Hypertension (≥130/85 mmHg or on antihypertensive therapy) is one of the five core NCEP-ATP III criteria for metabolic syndrome. Elevated blood pressure reflects endothelial dysfunction and sodium retention secondary to insulin resistance, making it a cardinal feature. This is a true criterion, not an exclusion. **B. Central obesity** — Central/abdominal obesity (measured by waist circumference) is the **first and most important** criterion in ATP III and is present in nearly all metabolic syndrome cases. It is the hallmark of insulin resistance. Indian guidelines (IDF, ICMR) emphasize lower waist circumference cutoffs (>90 cm men, >80 cm women) due to ethnic differences. This is definitionally required. **C. Hypertriglyceridemia** — Elevated triglycerides (≥150 mg/dL) are a core ATP III criterion reflecting impaired lipoprotein metabolism in insulin resistance. Hypertriglyceridemia is part of the atherogenic dyslipidemia triad (high TG, low HDL, small dense LDL particles). This is a true diagnostic component, not excluded. ## High-Yield Facts - **NCEP-ATP III metabolic syndrome** requires ≥3 of 5 criteria: central obesity, elevated TG, reduced HDL, elevated BP, elevated fasting glucose—LDL is NOT included. - **Indian cutoffs for central obesity** are waist circumference >90 cm (men) and >80 cm (women), lower than ATP III due to ethnic susceptibility to insulin resistance. - **Atherogenic dyslipidemia** in metabolic syndrome features high triglycerides + low HDL + small dense LDL particles; LDL *quantity* is not diagnostic but *quality* (particle size) matters. - **Metabolic syndrome prevalence** in urban India is 15–30%, with central obesity and hypertension being the most prevalent components. - **HDL reduction** (<40 mg/dL men, <50 mg/dL women) is a criterion; LDL elevation is common but not diagnostic for the syndrome itself. ## Mnemonics **ATP III Metabolic Syndrome (5 Components)** **ABCDE**: **A**bdomen (central obesity), **B**P (hypertension), **C**arbs (elevated fasting glucose), **D**yslipidemia (high TG + low HDL), **E**xtra risk. Remember: LDL is NOT part of the acronym. **What's IN vs OUT in Metabolic Syndrome** **IN**: Central obesity, Triglycerides ↑, HDL ↓, BP ↑, Glucose ↑. **OUT**: LDL (not diagnostic). Use this when differentiating syndrome diagnosis from general dyslipidemia workup. ## NBE Trap NBE pairs "dyslipidemia" with "LDL" to trap students who conflate metabolic syndrome diagnosis with general cardiovascular risk assessment. While LDL is important for CVD risk, it is not part of the ATP III metabolic syndrome definition—only HDL reduction and triglyceride elevation matter. ## Clinical Pearl In Indian urban practice, a 45-year-old man with central obesity, hypertension, and elevated triglycerides meets metabolic syndrome criteria even if LDL is normal or low—this is the **atherogenic dyslipidemia phenotype** common in insulin-resistant populations. Recognizing this distinction prevents over-reliance on statin therapy alone and redirects focus to insulin resistance management (weight loss, exercise, metformin). _Reference: Park's Textbook of Preventive and Social Medicine (Ch. Chronic Non-Communicable Diseases); NCEP-ATP III Guidelines; Harrison's Principles of Internal Medicine Ch. 242 (Metabolic Syndrome)_